Role of Calcium Channels in Vascular Function NCT02885558

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Details — Status: Completed

Study information
Verified date	May 2021
Source	University of Southern Denmark
Contact	n/a
Is FDA regulated	No
Health authority
Study type	Interventional

The purpose of this study is to examine the role of T-type calcium channels in endothelial dysfunction observed with ageing.

Recruitment information / eligibility
Status	Completed
Enrollment	12
Est. completion date	May 25, 2021
Est. primary completion date	May 25, 2021
Accepts healthy volunteers	Accepts Healthy Volunteers
Gender	All
Age group	20 Years to 70 Years
Eligibility	Inclusion Criteria: - age 20 - 30 and 60-70 - BMI < 30 Exclusion Criteria: - Hypertension (>150/90 mmHg) - Smoking - Physical activity >2 hours/week - Known chronic diseases - Pregnancy or birth within 3 month - Alcohol misuse

Drug:
• Efonidipine
8 weeks treatment with either efonidipine
• Nifedipine
8 weeks treatment with either nifedipine

Locations
Country	Name	City	State
Denmark	Centre for Phsical Activity Research	Copenhagen
Denmark	Cardiovascular and Renal Research	Odense

Sponsors *(1)*
Lead Sponsor	Collaborator
University of Southern Denmark

Denmark,

Outcome
Type	Measure	Description	Time frame	Safety issue
Primary	Vascular function	Hemodynamic response to femoral arterially infused vasoactive substances	8 weeks